Cerebrolysin

Cerebrolysin is a synthetic research peptide, a neuropeptide preparation derived from porcine brain tissue through enzymatic hydrolysis.  It is a complex mixture of low molecular weight peptides (molecular weight < 10,000 Da) and free amino acids. The preparation contains approximately 25% low molecular weight peptides and 75% free amino acids, including all essential amino acids as well as bioactive peptide fragments that can mimic endogenous neurotrophic factors such as brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF). Cerebrolysin is approved for clinical use in dozens of countries across Europe and Asia for the treatment of stroke, traumatic brain injury, vascular dementia, and cognitive impairment.

Cerebrolysin exerts its pleiotropic neuroprotective and neurotrophic effects through multiple interconnected mechanisms. It functions as a multimodal neuropeptide agent that mimics the activity of endogenous neurotrophic factors, promoting neurogenesis, neuroplasticity, and neuronal survival. Key mechanisms include inhibition of apoptosis, modulation of synaptic plasticity, and regulation of inflammatory responses. Cerebrolysin reduces excitotoxicity by modulating cell-death proteins including JNK, PTEN, Calpain, and Caspase-3, while also suppressing inflammatory pathways and stabilizing the blood–brain barrier. The preparation can cross the blood–brain barrier and exerts neurotrophic effects similar to endogenous growth factors.

• Ischemic Stroke: Investigated as an adjunct neuroprotective therapy in acute ischemic stroke, with studies examining its potential to improve functional outcomes when combined with reperfusion therapy.
• Traumatic Brain Injury: Studied for its neuroprotective and neurotrophic properties in supporting recovery following moderate to severe traumatic brain injury.
• Neurodegenerative Diseases: Employed in research on Alzheimer's disease, vascular dementia, and Parkinson's disease for its potential to improve cognitive function and slow disease progression.
• Neurogenesis and Plasticity: Utilized as a research tool to study neuronal regeneration, synaptic plasticity, and neurotrophic signaling pathways.
• Neuroinflammation: Used in preclinical models to evaluate anti-inflammatory effects and modulation of microglial responses.

CAS Number: 12656-61-0
UNII: 37KZM6S21G
Composition: ~25% low molecular weight peptides (< 10 kDa) and ~75% free amino acids
Purity: ≥ 99%
Form: Lyophilized powder
Storage: Store at ≤ -20°C in a cool, dry place, protected from light and moisture
Solubility: Soluble in sterile water; prepare working solutions per laboratory protocol